DNA vaccines, electroporation and their applications in cancer treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Numerous animal studies and recent clinical studies have shown that electroporation-delivered DNA vaccines can elicit robust Ag-specific CTL responses and reduce disease severity. However, cancer antigens are generally poorly immunogenic, requiring special conditions for immune response induction. To date, many different approaches have been used to elicit Ag-specific CTL and anti-neoplastic responses to DNA vaccines against cancer. In vivo electroporation is one example, whereas others include DNA manipulation, xenogeneic antigen use, immune stimulatory molecule and immune response regulator application, DNA prime-boost immunization strategy use and different DNA delivery methods. These strategies likely increase the immunogenicity of cancer DNA vaccines, thereby contributing to cancer eradication. However, cancer cells are heterogeneous and might become CTL-resistant. Thus, understanding the CTL resistance mechanism(s) employed by cancer cells is critical to develop counter-measures for this immune escape. In this review, the use of electroporation as a DNA delivery method, the strategies used to enhance the immune responses, the cancer antigens that have been tested, and the escape mechanism(s) used by tumor cells are discussed, with a focus on the progress of clinical trials using cancer DNA vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“Historically, striated muscles were first demonstrated to be a site of gene expression following naked DNA injection.(13) Subsequently, needle injection of DNAs encoding viral antigens into the muscle sites was reported to induce Ag-specific antibody and cellular responses (CTL responses, in particular) in influenza a…”
BackgroundInfluentialThe human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“In contrast, blocking CTLA-4 using antagonistic anti-CTLA-4 Abs is associated with increased antitumor T cell responses in mice.(55,56) Trp2- and gp100-encoding DNA vaccines in combination with anti-CTLA-4 Abs also displayed enhanced Ag-specific T cell responses and anti-melanoma activity in a B16 model.”
BackgroundPhase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“In contrast, blocking CTLA-4 using antagonistic anti-CTLA-4 Abs is associated with increased antitumor T cell responses in mice.(55,56) Trp2- and gp100-encoding DNA vaccines in combination with anti-CTLA-4 Abs also displayed enhanced Ag-specific T cell responses and anti-melanoma activity in a B16 model.”
BackgroundDistribution of DNA Vaccines Determines Their Immunogenicity After Intramuscular Injection in Mice
Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M. J., Chen, M., Otten, G. R., Ulmer, J. B., Donnelly, J. J., Ott, G., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2850 · Cited by 327 · cited 1×
“IM-EP also increases distribution and cellular uptake of DNA molecules at the injection sites.(32) In addition, the injection of needle probes and the application of subsequent electric pulses act to attract immune cells, including DCs, to the DNA injection sites, thus increasing the magnitude and duration of the Ag-s…”
Background
Cited by
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Molecular mechanisms for enhanced DNA vaccine immunogenicity
Li, L., & Petrovsky, N. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1124762 · Cited by 335
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
High-throughput 5’ UTR engineering for enhanced protein production in non-viral gene therapies
Cao, J., Novoa, E. M., Zhang, Z., Chen, W. C. W., Liu, D., Choi, G. C. G., Wong, A. S. L., Wehrspaun, C., Kellis, M., & Lu, T. K. (2021) · Nature Communications · doi:10.1038/s41467-021-24436-7 · Cited by 159
Metadata
- Authors
- Lee, S.-H., Danishmalik, S. N., & Sin, J.-I.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2015-05-18
- Volume
- 11
- Issue
- 8
- Pages
- 1889-1900
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W1537372914
- Cited by
- 76
- References
- 8
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNA vaccines, electroporation and their applications in cancer treatment. https://app.cochat.ai/papers/10.1080/21645515.2015.1035502
- The paper
- Lee, S.-H., Danishmalik, S. N., & Sin, J.-I. (2015). DNA vaccines, electroporation and their applications in cancer treatment. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2015.1035502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.